Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC

This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with Lenvatinib, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer.

Participants needed: 80
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Zhejiang Haichang Biotech Co., Ltd.Updated: Apr 20, 2026
Eligibility criteria

1. ≥18 years of age on the day of signing informed consent, male or female. 2. V... [+8]

1. Pregnant or breastfeeding patients or expecting to conceive or father childre... [+12]

Read more
Status: Not yet recruiting

Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with nivolumab, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer or advanced kidney cancer.

Participants needed: 230
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Zhejiang Haichang Biotech Co., Ltd.Updated: Mar 27, 2026Locations: 1
Eligibility criteria

1) Age 18-75 (inclusive) on the day of singing informed consent, male or female. [+12]

1) Pregnant or breastfeeding patients or expecting to conceive or father childre... [+11]

Read more
Status: Recruiting

Phase 2 Study of WGI-0301 for Advanced HCC

The purpose of this study is to determine the MTD of WGI-0301 in combination with Sorafenib for advanced Hepatocellular Carcinoma (HCC) and assess its safety and efficacy in adults with advanced unresectable HCC who have previously received PD-1 / PD-L1 immune checkpoint inhibitors.

Participants needed: 60
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Zhejiang Haichang Biotech Co., Ltd.Updated: Mar 19, 2026Locations: 4
Eligibility criteria

≥18 years of age on the day of signing informed consent, male or female. [+21]

Pregnant or breastfeeding patients or expecting to conceive or father children w... [+31]

Read more